Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2018

01-12-2018 | Research Article

Does NEMO/IKKγ protein have a role in determining prognostic significance in uveal melanoma?

Authors: M. K. Singh, N. Pushker, R. Meel, K. Chodsol, S. Sen, S. Bakhshi, L. Singh, S. Kashyap

Published in: Clinical and Translational Oncology | Issue 12/2018

Login to get access

Abstract

Purpose

Uveal melanoma, although a rare form of cancer, is the most common primary malignancy of the eye in adults. Nuclear factor-κB (NF-κB) is a transcription factor that transactivates genes involved in the regulation of cell growth, apoptosis, angiogenesis, and metastasis, but the molecular mechanisms that negatively regulate NF-κB activation are not fully understood. NF-κB can also be activated by DNA damage pathway through NEMO protein. Therefore, the objective of this study is to elucidate the role of NEMO/IKKγ protein in uveal melanoma patients.

Methods

Seventy-five formalin-fixed paraffin-embedded prospective tissues of uveal melanoma were included in the present study. These cases were reviewed and investigated for the expression of NEMO/IKKγ protein by immunohistochemistry and validated by western blotting along with the qRT-PCR for mRNA expression. Expression levels were correlated with the clinicopathological parameters and patients’ outcome.

Results

Immunohistochemistry showed cytoplasmic expression of NEMO/IKKγ expression in only 22 out of 75 (29.33%) cases. This result was confirmed by western blotting, and correlated well with the immunohistochemical expression of NEMO/IKKγ protein (48 kDa). In addition, downregulation of this gene was found in 87.93% of the cases when compared with the normal tissues. On statistical analysis, loss of NEMO/IKKγ protein was correlated with neovascularization, high mitotic count, and presence of vascular loop (p < 0.05). There was less overall survival rate with low expression of NEMO/IKKγ protein in patients with uveal melanoma.

Conclusion

This was the first study suggesting the relevant role of NEMO/IKKγ protein, and highlights the prognostic significance with outcome in uveal melanoma patients. This protein might be used as a screening biomarker in these patients after large-scale validation and translational studies.
Literature
1.
Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140:612–7.CrossRef
2.
Kashyap Seema, Venkatesh Pradeep, Sen Seema, Khanduja Sumeet, Shrey Dinesh, Garg Sana Tinwala Satpal. Clinicopathologic characteristics of choroidal melanoma in a North Indian population: analysis of 10-year data. Int Ophthalmol. 2014;34:235–9.CrossRef
3.
Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72.CrossRef
4.
McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.CrossRef
5.
Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. Ophthalmology. 2012;119:1582–9.CrossRef
6.
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V Twelve-year mortality rates and prognostic factors: COMS report No 28. Arch Ophthalmol. 2006;124:1684–93.CrossRef
7.
Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334–6.CrossRef
8.
Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin. 2006;46:151–66.CrossRef
9.
Brasiuniene B, Sokolovas V, Brasiunas V, Barakauskiene A, Strupas K. Combined treatment of uveal melanoma liver metastases. Eur J Med Res. 2011;16:71–5.CrossRef
10.
Aigelsreiter A, Haybaeck J, Schauer S, Kiesslich T, Bettermann K, Griessbacher A, Stojakovic T, Bauernhofer T, Samonigg H, Kornprat P, Lackner C, Pichler M. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol. 2012;43:1012–9.CrossRef
11.
12.
Chen F, Beezhold K, Castranova V. Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol. 2008;27:183–204.CrossRef
13.
Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998;395:297–300.CrossRef
14.
Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–32.CrossRef
15.
Aradhya S, Woffendin H, Jakins T, Bardaro T, Esposito T, Smahi A, Shaw C, Levy M, Munnich A, D’Urso M, Lewis RA, Kenwrick S, Nelson DL. A recurrent deletion in the ubiquitously expressed NEMO (IKK-gamma) gene accounts for the vast majority of incontinentia pigmenti mutations. Hum Mol Genet. 2001;10(19):2171–9.CrossRef
16.
Zonana J, Elder ME, Schneider LC, Orlow SJ, Moss C, Golabi M, Shapira SK, Farndon PA, Wara DW, Emmal SA, Ferguson BM. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet. 2000;67:1555–62.CrossRef
17.
Nogai H, Wenzel SS, Hailfinger S, Grau M, Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, Dietze K, Madle H, Tzankov A, Hummel M, Dörken B, Scheidereit C, Janz M, Lenz P, Thome M, Lenz G. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Blood. 2013;122:2242–50.CrossRef
18.
Madge LA, May MJ. Inhibiting proinflammatory NF-kappaB signalling using cell-penetrating NEMO binding domain peptides. Methods Mol Biol. 2009;512:209–32.CrossRef
19.
McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502–9.CrossRef
20.
The AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th edition classification of uveal melanoma. JAMA Ophthalmol. 2015;133:376–83.CrossRef
21.
Griewank KG, Murali R. Pathology and genetics of uveal melanoma. Pathology. 2013;45:18–27.CrossRef
22.
Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119–27.CrossRef
23.
Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128:871–5.CrossRef
24.
Baeuerle PA, Henkel T. Function and activation of NF-κ B in the immune system. Annu Rev Immunol. 1994;12:141–79.CrossRef
25.
Hayden MS, West AP, Ghosh S. NF-κB and the immune response. Oncogene. 2006;25:6758–80.CrossRef
26.
27.
Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege Y, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akira S, Tacke F, Heikenwalder M, Trautwein C, Luedde T. TAK1 suppresses a NEMO-dependent but NF-kappaB–independent pathway to liver cancer. Cancer Cell. 2010;17:481–96.CrossRef
28.
Rishi P, Koundanya VV, Shields CL, Using risk factors for detection and prognostication of uveal melanoma. Indian J Ophthalmol. 2015;63110–6.
29.
Shields CL, Manalac J, Das C, Ferguson K, Shields JA. Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 2014;25:177–85.CrossRef
30.
Jager MJ, Ly LV, El Filali M, Madigan MC, Macrophages in uveal melanoma and in experimental ocular tumor models: friends or foes? Prog Retin Eye Res. 2011;30:129–46.CrossRef
Metadata
Title
Does NEMO/IKKγ protein have a role in determining prognostic significance in uveal melanoma?
Authors
M. K. Singh
N. Pushker
R. Meel
K. Chodsol
S. Sen
S. Bakhshi
L. Singh
S. Kashyap
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1895-3

Other articles of this Issue 12/2018

Clinical and Translational Oncology 12/2018 Go to the issue

Correspondence

Letter to the Editor

Research Article

Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer

Review Article

This is a call to oncologists for action

Research Article

Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models

Research Article

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

Research Article

Management of patients with implanted cardiac devices during radiotherapy: results of a Spanish survey in radiation oncology departments
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits